knowledge -WSS

knowledge

author：knowledge 2025-09-29 00:38:41 - browse：46368

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Testing for cancer recurrence creates a new limbo for patients

hotspot

WSS

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

WHO may add ‘noma' to its list of neglected tropical diseases

FDA has safety concerns on CRISPR

Diversifying clinical trials isn't enough to close racial gaps: study

Cassava reveals details — and problems — with Alzheimer's study

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

hotspot

knowledge

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Senate panel to vote on hospitals, PBMs, prisoner care

New air purifier tech could be key to improving indoor air quality

Diversifying clinical trials isn't enough to close racial gaps: study

What does generative AI mean for health care? We asked experts

The painfully weak evidence on taking collagen to treat arthritis

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Maker of FluMist seeks to allow at

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Paying for Covid pills will soon shift to insurers

explore

WHO may add ‘noma' to its list of neglected tropical diseases

Lessons Learned: This is why you network to find that industry job you want

Senate panel to vote on hospitals, PBMs, prisoner care

Ohioans vote in high

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Readout Newsletter: New research from Sanofi, Regeneron, etc.

knowledge

hotspot

focus

hotspot